Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aspire Biopharma Holdings, Inc. - Warrant (NQ:ASBPW)

0.0300 -0.0024 (-7.41%)

Streaming Delayed Price Updated: 10:42 AM EST, Dec 3, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	7,219
Open	0.0300
Bid (Size)	0.0211 (3,000)
Ask (Size)	0.0315 (20,000)
Prev. Close	0.0324
Today's Range	0.0300 - 0.0308
52wk Range	0.0100 - 0.1200
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

December 02, 2025

Via ACCESS Newswire

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

November 26, 2025

Via ACCESS Newswire

Performance

YTD	-59.2%	-59.2%
1 Month	-25.0%	-25.0%
3 Month	-42.2%	-42.2%
6 Month	-23.3%	-23.3%
1 Year	-59.2%	-59.2%

More News

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

November 06, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

October 06, 2025

Via ACCESS Newswire

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

October 03, 2025

Via ACCESS Newswire

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

October 01, 2025

Via ACCESS Newswire

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

September 17, 2025

Via ACCESS Newswire

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

September 16, 2025

Via ACCESS Newswire

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

September 03, 2025

Via ACCESS Newswire

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

August 18, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

August 14, 2025

Via ACCESS Newswire

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

August 13, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

July 31, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc. Announces CEO Transition

July 30, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

July 22, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Positive Consumer Feedback from Company Sampling of BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement

July 09, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

June 24, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer

June 10, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025

May 28, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

May 20, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21

May 08, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

April 29, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17

April 14, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement

April 11, 2025

Via ACCESS Newswire

Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

April 09, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is Aspire Biopharma Holdings, Inc. - Warrant publicly traded?

Yes, Aspire Biopharma Holdings, Inc. - Warrant is publicly traded.

What exchange does Aspire Biopharma Holdings, Inc. - Warrant trade on?

Aspire Biopharma Holdings, Inc. - Warrant trades on the Nasdaq Stock Market

What is the ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant?

The ticker symbol for Aspire Biopharma Holdings, Inc. - Warrant is ASBPW on the Nasdaq Stock Market

What is the current price of Aspire Biopharma Holdings, Inc. - Warrant?

The current price of Aspire Biopharma Holdings, Inc. - Warrant is 0.0300

When was Aspire Biopharma Holdings, Inc. - Warrant last traded?

The last trade of Aspire Biopharma Holdings, Inc. - Warrant was at 12/03/25 10:42 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.